PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22710762-10	2013	Bcl-2 expression tended to be increased after addition of thalidomide.	Thalidomide	58-69	BCL2 apoptosis regulator	Homo sapiens	0-5	
19372569-4	2009	Curcumin also potentiated the apoptotic effects of thalidomide and bortezomib by down-regulating the constitutive activation of NF-kappaB and Akt, and this correlated with the suppression of NF-kappaB-regulated gene products, including cyclin D1, Bcl-xL, Bcl-2, TRAF1, cIAP-1, XIAP, survivin, and vascular endothelial growth factor.	Thalidomide	51-62	BCL2 apoptosis regulator	Homo sapiens	255-260	
15982930-7	2005	Thalidomide reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60.	Thalidomide	0-11	BCL2 apoptosis regulator	Homo sapiens	66-71	
16523333-14	2006	In most patients, the BCL-2/BAX ratio was lower in cell cultures supplemented with mixture of lovastatin and thalidomide in comparison with cell cultures supplemented with lovastatin or thalidomide alone.	Thalidomide	109-120	BCL2 apoptosis regulator	Homo sapiens	22-27	
16523333-14	2006	In most patients, the BCL-2/BAX ratio was lower in cell cultures supplemented with mixture of lovastatin and thalidomide in comparison with cell cultures supplemented with lovastatin or thalidomide alone.	Thalidomide	186-197	BCL2 apoptosis regulator	Homo sapiens	22-27	
15167912-12	2004	Additionally, a dramatic decrease in Bcl-2 expression with s-thalidomide suggests a possible enhancement of cytotoxic effect if combined with other cytotoxic agents.	Thalidomide	59-72	BCL2 apoptosis regulator	Homo sapiens	37-42	
27748909-3	2016	Thalidomide was added to osteosarcoma cells and studied by cytotoxicity assay, evaluating apoptosis, cell cycle arrest, mitochondrial membrane potential (DeltaPsim), and reactive oxygen species (ROS) levels and the expression of Bcl-2, Bax, caspase-3 and NF-kappaB.	Thalidomide	0-11	BCL2 apoptosis regulator	Homo sapiens	229-234	
27748909-8	2016	By western blot analysis, thalidomide resulted in the decreasing expression of Bcl-2 and NF-kappaB, and the increasing expression of Bcl-2/Bax and caspase-3.	Thalidomide	26-37	BCL2 apoptosis regulator	Homo sapiens	79-84	
27748909-8	2016	By western blot analysis, thalidomide resulted in the decreasing expression of Bcl-2 and NF-kappaB, and the increasing expression of Bcl-2/Bax and caspase-3.	Thalidomide	26-37	BCL2 apoptosis regulator	Homo sapiens	133-138	
27129176-11	2016	We concluded that the addition of thalidomide to the CHOP regimen significantly improved the CRR and showed a trend of improving clinical outcome in patients with DLBCL, especially for patients with Bcl-2 positive and Bcl-6 negative B-cell phenotype, without increased toxicity.	Thalidomide	34-45	BCL2 apoptosis regulator	Homo sapiens	199-204	
27629726-9	2016	Forty-eighthour treatment of thalidomide 350 mug/mL and IFN 1400 U/mL could significantly decrease Bcl-2 expression and increase the expression levels of phosphor-P38, BAX, cytochrome c, and cleaved caspase-3, -8, and -9 as compared to the control group.	Thalidomide	29-40	BCL2 apoptosis regulator	Homo sapiens	99-104